Results for this period
Full year1 April 2025–31 March 2026ConsolidatedJapanese GAAPThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Stacked from zero: upward is an increase in cash, downward a decrease (in ¥ million).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.
In Japan, sales of medical gloves and urination and drainage-related products declined, while overseas sales of blood bags and apheresis blood collection circuits for North America decreased. Sales of closed systems for drug preparation and administration, products related to eating and swallowing, and AVF needles increased. Operating income was affected by lower sales of blood bags and apheresis blood collection circuits, while the bottom line fell into the red due to the recognition of a loss on business restructuring related to the restructuring of the production base in South Korea.
None ("There are no applicable matters.")
| Item | Details |
|---|---|
| Fiscal Period Classification | Full year |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 April 2025–31 March 2026 |
| Net Sales | ¥65,845 million (YoY -5.6%) |
| Operating profit | ¥381 million (YoY -56.3%) |
| Ordinary income | ¥356 million (YoY -30.8%) |
| Profit attributable to owners of the parent | ¥-783 million |
| Net income per share | (¥31.97) |
| Operating Margin | 0.6% (1.3% in the previous period) |
| Equity ratio | End of the current fiscal period 50.2％ / End of previous period 50.1％ |
| Total assets | ¥83,067 million |
| Net assets | ¥41,791 million |
| Cash flows from operating activities | ¥1,584 million |
| Cash flows from investing activities | ¥-2,250 million |
| Cash flows from financing activities | ¥2,687 million |
| Cash and cash equivalents at end of period | ¥7,717 million |
| Full-year earnings forecast | Net Sales ¥66,000 million (YoY +0.2%) / Operating profit ¥1,000 million (YoY +162.1%) / Ordinary income ¥900 million (YoY +152.4%) / Profit attributable to owners of the parent ¥600 million |
| Annual Dividend Forecast | ¥17 → ¥17（0.0%） |
| Payout ratio | 69.4% (forecast for the fiscal year ending March 2027) |
| Segment revenue | Japan ¥44,759 million (YoY -2.8%) / Singapore ¥23,726 million (YoY -10.6%) / China ¥3,985 million (YoY -4.3%) / Philippines ¥3,335 million (YoY -8.9%) / Germany ¥3,956 million (YoY -11.5%) |
| Segment profit | Japan ¥949 million (YoY -36.0%) / Singapore ¥-47 million / China ¥87 million / Philippines ¥-727 million / Germany ¥473 million (YoY +4.1%) |
| Regional sales | Japan ¥44,759 million (YoY -2.8%) / Singapore ¥23,726 million (YoY -10.6%) / China ¥3,985 million (YoY -4.3%) / Philippines ¥3,335 million (YoY -8.9%) / Germany ¥3,956 million (YoY -11.5%) / Other ¥5,929 million (YoY +17.5%) |
| Depreciation and amortization | ¥3,796 million |
| Impairment loss | ¥76 million |
| Breakdown of extraordinary income (loss) | Extraordinary income Gain on sale of non-current assets ¥15 million, Gain on sale of investment securities ¥310 million / Extraordinary loss Loss on sale of fixed assets ¥10 million, Loss on disposal of fixed assets ¥30 million, Impairment Losses ¥76 million, Business restructuring loss ¥934 million |
| Disclosure regarding the going concern assumption | None ("There are no applicable matters.") |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No |
| Changes in the scope of consolidation | New Not disclosed / Excluded Not disclosed / Description No |
| Material subsequent events | At a meeting of the Board of Directors held on 17 April 2026, the Company decided to construct a new head office at its current headquarters site, comprising research and development facilities and offices. Construction is scheduled to begin in February 2027 and be completed in August 2031. The impact on financial results is currently under review. |
| Availability of Supplementary Financial Results Materials | Yes |
| Availability of Financial Results Briefing | Whether applicable Yes / Subject person Not disclosed |
| Issued Shares at Period-End | 24,733,466 |
| Treasury Shares at Period-End | 202,966 |
| Factors Behind Changes in Business Performance | In Japan, sales of medical gloves and urination and drainage-related products declined, while overseas sales of blood bags and apheresis blood collection circuits for North America decreased. Sales of closed systems for drug preparation and administration, products related to eating and swallowing, and AVF needles increased. Operating income was affected by lower sales of blood bags and apheresis blood collection circuits, while the bottom line fell into the red due to the recognition of a loss on business restructuring related to the restructuring of the production base in South Korea. |
Items this document does not state (3)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Declines in sales of medical gloves, urination and drainage-related products, blood bags, and apheresis blood collection circuits for North America weighed on net sales and operating income. The Company also recorded interest expense and foreign exchange losses, as well as a ¥934 million loss on business restructuring related to the restructuring of its production base in South Korea as an extraordinary loss. For the next fiscal year, the Company expects overseas demand to recover and expand, along with the benefits of structural reform, price pass-through, and cost reductions.